上海君實生物醫藥科技股份有限公司
Shanghai Junshi Biosciences Co., Ltd.*
( 於中華人民共和國註冊成立的股份有限公司 )
股份代號 : 1877
年度報告
2020
* 僅供識別
2
4
10
12
48
62
79
131
168
172
174
176
178
181
274
2
3
4
2
1
3
4
5
2
3
Roy Steven Herbst
4
Roy Steven Herbst
5 5
6
7
2
4
5
3
872,496,000 182,746,500 H
36 58 2 13 689,749,500 A
16 H
183 54 200 H
H
www.junshipharma.com
183 54
1
2020 10 14
2
2020 6 19
3
2020 11 16
4
2020 11 16
5
2020 6 19
6
2020 11 16
7
2020 11 16
H 01877
A 688180
4
2020 12 31 1,595 2019 106%
1,003 89%
405
1,778 2019 88% (i)
(ii)
(ADC)
4,414 A 2020 7 15
4,497
1,688 2019 128%
FDA 1 1
3 NMPA
2020 7 NMPA
15 30
5
2020 9
III 2021
2
NMPA
2020 12 III
30 28 2
TAB004/JS004 BTLA 2020 1 NMPA
2020 4 I Ia
Ib/II
JS005 IL-17A 2020 5 I
I II
JS108 Trop2 Tub196 2020 7 NMPA
2020 11
TAB006/JS006 TIGIT 2020 11 2021 2 NMPA FDA
6
COVID-19
etesevimab JS016
2020 5 COVID-19
etesevimab
JS016 SARS-CoV-2
etesevimab
I Ib/II
FDA etesevimab 1,400mg bamlanivimab 700mg
COVID-19 COVID-19
(NIH) COVID-19 etesevimab bamlanivimab
COVID-19
(EMA) (CHMP) etesevimab bamlanivimab
7
Revitope Oncology, Inc. Revitope Limited Revitope
Revitope T
T
PARP
senaparib 50% senaparib
CD39 CD39
CD39
50% 50%
XPO1 Aurora-A EGFR-exon20
EGFR
A 2020 7 15
8
12 31
2016 2017 2018 2019 2020
3,757 1,148 934 775,089 1,594,897
2,771 702 667 684,405 1,222,366
(131,490) (320,802) (716,500) (744,233) (1,665,639)
(128,667) (326,915) (714,593) (741,055) (1,687,567)
(127,720) (326,688) (714,654) (740,744) (1,687,567)
(947) (227) 61 (311) –
(0.26) (0.55) (1.19) (0.95) (2.02)
(1.19) (0.95) (2.02)
12 31
2016 2017 2018 2019 2020
604,122 708,703 1,347,126 2,511,324 3,312,147
544,908 511,006 2,910,184 1,911,116 4,698,717
1,149,030 1,219,709 4,257,310 4,422,440 8,010,864
3,453 41,815 465,112 828,548 677,022
18,962 58,560 471,065 605,376 1,492,582
22,415 100,375 936,177 1,433,924 2,169,604
1,126,615 1,119,334 3,321,133 2,988,516 5,841,260
2016 2017
9
12 31
2016 2017 2018 2019 2020
*
5,939 54,500 2,928 775,089 1,594,897
2,646 48,373 (1,269) 677,105 1,214,645
(136,269) (317,571) (722,854) (747,729) (1,668,607)
(128,667) (326,915) (721,582) (744,550) (1,690,536)
(0.27) (0.55) (1.21) (0.96) (2.03)
12 31
2016 2017 2018 2019 2020
596,082 704,380 1,340,137 2,500,838 3,298,693
552,948 515,328 2,910,184 1,911,116 4,698,717
1,149,030 1,219,708 4,250,321 4,411,954 7,997,410
3,452 41,815 465,111 855,700 697,140
18,963 58,560 471,067 578,225 1,472,464
22,415 100,375 936,178 1,433,925 2,169,604
1,126,615 1,119,333 3,314,143 2,978,029 5,827,806
*
10
2020
2020
2020 15 30
FDA 1 1 3
JS004 BTLA JS006 TIGIT JS005 IL-17A
I JS108 Trop2 Tub196
2020
4
PD-1
11
2020
7 A+H
30 (ADC)
2021
Coherus
2021
FDA NMPA
JS201(PD-1/TGF-β) JS110 XPO1
JS111 EGFR exon20 JS103
15
2021 3 30
12
first-in-class
best-in-class
JS001
NMPA PD-1
JS002 UBP1213 NMPA IND PCSK9 BLyS
TAB004/JS004 (first-in-human) BTLA
FDA NMPA 2020
etesevimab JS016 2021 2
FDA etesevimab (JS016/LY-CoV016) 1,400mg bamlanivimab
(LY-CoV555) 700mg
(ADC)
2020 COVID-19
13
1,003
2020 12
2020 12 31 900 300
1,500 1,100 2021 2
15 30
FDA 1 1
3 2021 3 FDA
BLA FDA (Rolling Review) FDA BLA PD-1
2021 2
NMPA NDA
2020 5 NMPA 2020 7 NMPA 2021 2
NMPA
14
COVID-19 etesevimab JS016
IND GLP
GMP etesevimab
etesevimab
I Ib/II
2021 2 FDA etesevimab 1,400mg bamlanivimab
700mg COVID-19 COVID-19
(NIH) COVID-19 etesevimab bamlanivimab
COVID-19 (EMA) (CHMP)
etesevimab bamlanivimab etesevimab bamlanivimab
COVID-19 COVID-19 12 COVID-19
Coherus BioSciences, Inc. Coherus
etesevimab 1,000
2.45
Coherus
Coherus Coherus JS006
TIGIT JS018-1 IL-2 2
11.1 Coherus
20%
Coherus Coherus Coherus
Coherus
15
30 (ADC)
Revitope
Revitope T
T PARP
senaparib 50% senaparib
XPO1 Aurora-A EGFR-exon20 EGFR
A 2020 7 15
JS004 JS001
16
2020 7 18A.09 18A.11 8.05(3)
B
2021 2 A H H (1877.HK)
A (688180.
SH) 50 2021 3 15
(license-in)
30
(ADC)
17
NCT03013101 2018 12 17
NCT02915432 2021 2 NMPA FDA BLA FDA
NCT03581786 NDA
NCT03113266 NDA
NCT03856411
NCT03924050
NCT04772287
NCT04012606
NCT03829969
/
JS001
NCT03430297
NCT04085276
NCT04523493
NCT04723004
NCT03859128
NCT02915432
NCT04394975
NCT04568304 PD-L1+
FDA
/
NMPA
NCT03474640 FDA
JS003 PD-L1
JS004
BTLA
(TAB004)
JS006 TIGIT
JS007 CTLA-4
JS101 Pan-CDK
JS108 TROP2
JS109 PARP
BRCA
JS110 XPO1
JS111 EGFR exon 20
JS201 PD-1/TGF-β
JS501 VEGF
JS002 PCSK9
JS103 Uricase
UBP1211 NDA
TNF-α
JS005 IL-17A
UBP1213 BLyS
EUA FDA
JS016
S
(Etesevimab)
18
19
JS009 CD112R/ PVRIG
JS011
JS012
JS014 IL-21 100%
JS018 IL-2 100%
JS019 CD39 50%
JS104 Pan-CDK 50%
JS105 PI3K-α 50%
JS112 Aurora A 50%
JS113 EGFR 4th Gen 50%
JS008
JS010 CGRP
20
JS001
PD-1
2 2018 12 NMPA
2019 2020
(CSCO) 2020 12
2021 2
NMPA
1,003 2020 12 31
900 300 1,500 1,100
PD-1
2021 2
21
15 30
2020 5 NMPA 2020 7 NMPA 2020 12
III CHOICE-01(NCT03856411)
NMPA
2021 2
NMPA 2021 3 NMPA
FDA 1
1 3
2021 3 FDA
FDA
FDA FDA
FDA BLA PD-1
22
2021 2 Coherus Coherus
Coherus
1.5 3.8
Coherus 20% BLA
Coherus FDA
2020 1 Cancer Communications IF 5.627
2020 2 ASCO (ASCO-GU)
(POLARIS-03)
2020 4 (Clinical Cancer Research, IF 10.107
2020 4 (AACR 2020)
2020 5 (ASCO 2020)
9
2020 9 (ESMO 2020)
4
2020 9 (CSCO 2020)
9
4
23
2020 10 JAMA (JAMA Network Open IF 5.032)
2020 11 (STIC 2020)
2
2020 11 (ESMO ASIA 2020)
2021 1 21 (WCLC 2020)
CIK
2021 1 (Journal of Clinical Oncology IF 32.956)
(POLARIS-02)
JS001 112.68
Etesevimab JS016/LY-CoV016
Etesevimab SARS-CoV-2
COVID-19 2020 5
etesevimab 1,000
2.45
2021 2 FDA etesevimab JS016 LY-CoV016 1400mg bamlanivimab
(LY-CoV555) 700mg (EUA) COVID-19
COVID-19 (NIH) COVID-19
etesevimab bamlanivimab COVID-19
(EMA) (CHMP) etesevimab bamlanivimab
etesevimab bamlanivimab COVID-19
COVID-19 12 COVID-19
etesevimab
24
SARS-CoV-2
2020 6 etesevimab I 2020 7 I
I JS016
40
Ib/II
etesevimab I
(NCT04441931) COVID-19 II/III (BLAZE-1, NCT04427501)
2021 1 BLAZE-1 III etesevimab 2,800 mg
bamlanivimab 2,800 mg (COVID-19)
COVID-19 1,035 2.1% 11
7.0% 36 70% p=0.0004 10
etesevimab bamlanivimab Etesevimab bamlanivimab
BLAZE-4 (NCT04634409)
etesevimab 1,400 mg bamlanivimab 700 mg etesevimab 2,800 mg
bamlanivimab 2,800 mg
25
etesevimab bamlanivimab
NDA
UBP1211
UBP1211 2019 11 NMPA NDA
UBP1211
PCSK9 JS002
JS002 PCSK9
I II JS002
LDL-C 50-70%
III
26
BTLA TAB004/JS004
TAB004/JS004 (first-in-human) B T
(BTLA) BTLA TAB004/JS004 Ia
Ib/II TAB004/JS004 2020 1 NMPA IND 2020 4
I I
TIGIT TAB006/JS006
TAB006/JS006 TIGIT TAB006/JS006
TIGIT-PVR TIGIT T cell immunoglobulin and
ITIM domain, T ITIM NK T
PVR NK T
PD-1 T TIGIT PD-1/PD-L1
2021 1 TAB006/JS006 NMPA 2021 2 TAB006/JS006 FDA
TAB006/JS006
Trop2 Tub196 JS108
JS108 Trop2 Tub196 Trop2
Trop2 2020 7
JS108 NMPA 2020 11 JS108 I (NCT04601285) I
JS108 3
16-36 12-27 60-90
27
PARP senaparib JS109
Senaparib -ADP (PARP) 2019 ASCO I
senaparib PARP 2020 8
senaparib
PARP senaparib
50% 2020 8 20 26
senaparib II BRCA
senaparib III
PD-1/TGF-β JS201
JS201 PD-1 TGF-β -β PD-1
TGF-β TGF-β PD-1
PD-1 TGF-β JS201 PD-1/PD-L1 TGF-β
2021 2 NMPA JS201
XPO1 JS110
JS110 XPO1 JS110
XPO1 p53 JS110
JS110
JS110 2021 2
NMPA JS110
JS110
28
EGFR exon20 JS111
JS111 EGFR EGFR EGFR
10% EGFR exon20 T790M G719X
18-21 EGFR-TKI EGFR exon20 EGFR
JS111
T790M EGFR EGFR EGFR exon20
EGFR JS111 EGFR exon20 EGFR
2021 2 NMPA
JS111 JS110
JS103
JS103
(2019)
13.3% 1.1% JS103
2021 3 NMPA JS103
IL-17A JS005
JS005 IL-17A 2020 5 JS005 I
I II JS005
IL-17 JS005
29
2020 7 Revitope Revitope T
T Revitope
5 TEAC
2020 7 14
2020 8 IL-2
IL-2 JS018
2020 8 28
2020 9 XPO1
Aurora-A EGFR-exon20 EGFR
50%
2020 9 16
2020 9 CD39
50% 50% CD39
ATP (ADO)
CD39
3 CD39
CD39 CD39
2020 9 9
30
2 GMP 3,000L 6*500L
CGMP
30,000L 15*2,000L 2019
JS016
A 2020 7 15
2020 7 18A.09 18A.11 8.05(3)
B
2021 2 A H H (1877.HK)
A (688180.SH) 50 2021 3 15
1,778
88% 70 55
15
31
2,453 667 912 603
59 212
32
1.
2020 12 31 1,595 106% (i)
1,102 42% 1,003 (ii)
405 2020 5
SARS-CoV-2 COVID-19
2.
2019 2020 12 31 946 1,778 2020
(i)
(ii)
(iii)
3.
2019 2020 12 31 320 688 2020
33
4.
2019 2020 12 31 217 443 2020
5.
2020 12 31 2019 12 31 1,214 3,385
(i) A 2020 7 15
(ii)
2020 12 31
13
92,508
34
6.
12 31
2020 2019
(1,687,567) (741,055)
– 23,426
1,102 4,345
30,728 11,797
11,672 2,266
(1,644,065) (699,221)
35
2019 2020 12 31
(a)
12 31
2020 2019
(1,665,639) (743,922)
12 31
2020 2019
824,816,637 783,624,056
(b)
2018 5 14 2020 11 16
2020 12 31 2019 12 31
36
2019 12 31 181 2020 12 31 343
12 31
2020 2019
277,288 129,081
31,887 35,004
34,250 16,581
343,425 180,666
12 31
2020 2019
17 17
a 77,030 –
b 133,007 69,345
c 146,688 –
356,725 69,345
37
(a)
(b)
(c)
68,199,000
12 31
2020 2019
589,207 157,505
74,116 –
663,323 157,505
– (89)
663,323 157,416
2019 1 1
38
12 31
2020 2019
0 30 573,437 96,647
31 90 27,876 60,235
91 180 61,103 534
180 907 –
663,323 157,416
2020 12 31 61,583,000 2019 8,540,000
90
2020 12 31 74,116,000 2019
39
12 31
2020 2019
90,706 74,616
106,018 112,561
a 215,933 98,561
31,656 14,979
b 210,552 –
c 30,149 –
48,330 30,004
64,354 –
205,026 113,311
19,620 10,409
– 13,565
d 68,199 –
32,625 –
91,848 46,633
1,215,016 514,639
40
15 60 2019 15 60
12 31
2020 2019
0 – 30 74,433 58,726
31 – 60 4,316 2,946
61 – 180 2,009 11,426
180 9,948 1,518
90,706 74,616
(a)
(b) 5
30
(c)
(d)
41
2020 12 31 20 3.75%
900 2019 9 12 2022 11 29
2020 12 31 800 5.23%
i) ii)
37
2020 12 31
2020 2019
1,716,673 1,607,916
58,862 62,425
1,775,535 1,670,341
252,346 76,891
542,222 –
– 744,896
794,568 821,787
2020 12 31
42
2020 12 31
528 2019 12 31 427 24%
3,400
100% 2020 12 31
2020 12 31 1,421
2020 A
28,519,000 2020 A
43
IND
PD-1
PCSK9 BLyS BTLA
30 28 2
(ADC)
1
2
3
44
1
2
3
4
2023
4,021 2018 2023 9.0%
45
1
2019
2
2020
1,778
88%
46
3
PD-1 PD-1
4
2020
2020 PD-1
47
5
4+7
UBP1211 JS501 28
6
2020
48
47
2015 3
2013 4
2013 1 2013 3 2015 11
430598.NEEQ 2016 6
2013 9 2015 11 2007 2
1996 7 2007 12
2017 2020 12 31
218,051,536 A 2,600 H
49
60
2018 6
2018 1
1994 5 1997 1 (NIH) AIDS
WESTAT 1997 2 2009 12 FDA
2009 9 2018 1
2007 1 2010 12 (Johns Hopkins)
2010 11 2012 11 2012 1 2014 12
1984 7 1987 10
1994 8
2020 12 31 1,560,000 A
45
2015 3
2014 1
10
2003 2007 2007 2010 HumanZyme Inc.
2010 10 2013 11 MedImmune Inc.
TopAlliance
JS001 JS002 JS003
1997 7 2003 9
2020 12 31 13,960,000 A
50
54
2016 12
2012 12
20 2011 11 2015 11 2008
7 2015 11 2013 10
2016 5 2018 6 2016 4
2012 12 2012 12 2013 3
2013 10
1997 1 2004 5
2005 5 2008 10 Viron Therapeutics Inc. 2008 11 2011 9
2011 2
1988 7 1995 7
2005
2020 12 31 9,428,000 A
46
2016 12
2014 6
2004 5 2010 12
2011 1 2011 10 2011 10 2014 6
Amplimmune Inc.
TopAlliance JS002 JS003
1998 6 2003 1
(Nature Communications)
(Science Advances) (Immunity) Jem Blood JI
2020 12 31 2,000,000 A
51
48
2020 10
2016 12
2013 6
20 2003 3 2007 9
2007 8 2009 2 Trellis Biosciences 2009 2 2013 5 Amgen
2016 12 2020 10 14
JS002 JS003
1994 7 2002 5
(Nature) (Science) (EMBO)
20
53
2015 5
2015 5
20 1991 1993
1993 1996 1996 6
2010 12 2010 10
2013 10 002650.SZ
2011 6 2018 11
832549.NEEQ 2017 8 2013 4
2013 7 2017 7
1989 7 1990 1
2020 12 31 204,145,236 2,600 H
52
57
2016 12
2016 12
17 1986 7 1997 12
1997 12 2004 1
2004 1 2019 3
600867.SH
1986 7
2020 12 31 3,657,600 A
49
2016 12
2016 12
2005
1995 8 2001 5 2003 11 2006 1
2018 12 2019 11
6998.HK 2020 8
6618.HK
1995 7 2003 5
2014 10
BGNE.NASDAQ 6160.HK
53
48
2018 6
2018 6
2015 9 2015 6
1997 7 2001 7
2004 5 2015 4 2015 7 2021 2
836484.NEEQ
2017 6 2120.HK
2018 11 9969.HK
2019 11 2020 8
9926.HK 2014 6 2017 3
600649.SH 2017 9 2020
10 600825.SH 2016 4 2020 9
YIN.US 2016 3 2019 6
3666.HK 2015 11 2019 3
376.HK
1994 6 1997 6
2003 6
2020 12 31 78,852,000 A 37,189,000 H
54
64
2018 6
2018 6
35 1999 B7-H1 PD-L1
PD-L1 1999 2002 PD-1/PD-L1
2006 PD-1 PD-L1
1990 1997 (Bristol-Myers Squibb
Company) 1997 1999 2004 2011
2011
SPORE
60%
2017 4 17 2
15%
2016 9 27 300
55
1982 1986
1989
William B. Coley 2014 AAI-Steinman 2016 Warren Alpert
2017 2018
64
2020 6
2020 6
1978 8 1992 7
1992 8 1993 12 1993 12 1995 12
1995 12 1999 12 1999 12
2010 9 2010 9 2017 8 2017
8
1985 7 2001 12 1994
1997 12
56
2020 11
2020 11
1997 11
2014 2 2019 4 2004 12
2014 2 1995 9 1997 11
1999 7 1999 12 1997
2 1997 7 2001 8 2002 2
2019 11 9966.HK
2021 1 2160.
HK
56
1987 7 1992 7
1995 7 2017
53
2018 6
2018 6
1989 8 1995 3 1995 3 1999 7
1999 7 1999 12 2000 1 2006 3
2006 3
1989 7 2004 12
2015 11 2017 9
2017 12
Roy Steven Herbst 58
2018 6
2018 6
Herbst 1991 1997 1998 2011
(UTMDACC) Barnhart
2011 3
Smilow Cancer Hospital I
Herbst 1984 6 1990 6
1991 5 Cornell University Medical College 1997
11 2012 12
57
36
2018 6
2018 6
2011 3 2014 3 2016
1 2017 4 華泰證券股份有限 2017 10
2008 7 2011 1
39
2018 6
2018 6
2006 3 2003 6
2006 1 2006 9
29
2019 5
2017 8
2017 4
42
2019 6
2019 6
2007 5 2009 10 2009 10 2016 9
2016 9 2000 7 2006 5
58
44
2020 11
2020 10
2020 10 2006
6 2009 7 2009 7 2010 11
2010 11 2015 9
2015 9 2018 4 ADC 2018 4 2020
10 CMC
2000 2005
64
2019 8 1995 10
1998 6 1998 6 1999 7 Osiris Therapeutics
1999 8 2003 8 2003 8 2005 6
2005 6 2017 4 FDA
2017 4 2018 4 NMPA 2018
5 2019 8 1995
49
2019 7 1994 7 1998 12
1999 3 2000 8 2000 9 2001 4
2001 5 2002 5 2002 6 2006
7 2006 8 2011 7
2011 8 2017 11
2017 12 2018 2 2018
3 2019 4 2017 7
59
57
2020 8 1984 8 1993 6
1993 6 1994 7 1994 7 1997 9
1997 9 2002 11 2002 11
2003 9 2003 9 2005 4
2005 5 2005 11 2005 11
2009 10 2009 10 2012 2
2012 2 2016 7 1984
2005
48
2020 8 1995 7 2010 11
2010 11 2016 4
1995
57
2020 8 1985 6 1993 6
1993 6 1994 4
1997 9 2000 10 Bechtel 2000 11 2001 3
2001 4 2005 4 2005 4
2009 5 2009 5 2010 10
2010 10 2013 2 2013
2 2019 2 2015 6 2019 2
2019 2 2019 12
1985
2009
60
42
2020 11 2004 6 2011 5
2011 5 2013 4 2013
4 2020 2 2020 2 2020 11
2004
39
2018 6 2018 6 2020 11 2020 11
10 2007 4 2009
7 2009 8 2011 5
(Bosch (China) Co., Ltd.) 2011 5
2017 9 BU-Adhesive Consumer China 2017 9
2018 6 2004 7
2007 1
30
2018 1 2017 4 2017 4 2018 1
2014 7 2015 11
2017 11
2019 10
2020 10
61
2020 1 14
2020 1
頴 2020 1 14
2018 12 2020 1
25
62
2020 12 31
63
15 5 5 5
2020 10 14
2020 6 19
2020 11 16
Roy Steven Herbst
48 61
64
3.13
A.4.1 A.4.2
2020 2021
3 30
Roy Steven Herbst
2020
65
66
2020 12 31
A/B
A/B
A/B
A/B
A/B
2020 10 14 A/B
A/B
A/B
A/B
A/B
A/B
2020 6 19 A/B
2020 11 16 A/B
A/B
Roy Steven Herbst A/B
2020 6 19 A/B
2020 11 16 A/B
A
B
67
3.10(2)
(i)
(ii) (iii)
2020
12
68
69
47 6 2015 3 27
60 2 2018 6 24
45 6 2015 3 27
54 4 2016 12 22
46 4 2016 12 22
2020 10 14 48 4 2016 12 22
53 5 2015 5 30
57 4 2016 12 22
49 4 2016 12 22
47 2 2018 6 24
64 2 2018 6 24
2020 6 19 66 1 2018 6 24
2020 11 16 48 1 2018 6 24
53 2 2018 6 24
Roy Steven Herbst 58 2 2018 6 24
2020 6 19 64 1 2020 6 19
2020 11 16 56 1 2020 11 16
70
1.
2.
a)
b)
c)
d)
e)
f)
g)
h)
71
Roy Steven Herbst
D.3.1
72
(1)
13/13 – 5/5 3/3 1/1 8/8
13/13 – 5/5 – 1/1 3/8
13/13 – – – – 3/8
13/13 – – – – 3/8
13/13 – – – – 3/8
2020 10 14 13/13 – – – – 3/8
13/13 – – – – 3/8
13/13 3/3 – – – 3/8
13/13 – – – – 3/8
13/13 – – – – 3/8
13/13 – – – 1/1 3/8
2020 6 19 5/13 1/3 2/5 – 1/1 0/8
2020 11 16 10/13 3/3 4/5 2/3 – 3/8
13/13 3/3 5/5 3/3 – 3/8
Roy Steven Herbst 13/13 – – – 1/1 3/8
2020 6 19 8/13 2/3 3/5 – – 3/8
2020 11 16 3/13 – 1/5 1/3 – 0/8
(1) 8 1 3 A H
2
73
74
168 171
3,080,000 4,259,000
3,080,000
3,080,000
4,259,000
900,000
1,000,000
2,359,000
7,339,000
75
2020 1 14 2020 1 14
3.29 15
10%
76
3%
3% 10
2
H
183 54
+852 2810 8185
36 58 2 13
201203
+86 021 8016 4691
+86 021
2250 0300
77
2020 2 3 2020 11 16
1.
2. A
E.1.5
(1)
(2)
(3)
10%
50%
78
25%
79
2020 1 1 2020 12 31 2020
TopAlliance Biosciences, Inc. TopAlliance
80
(www.hkex.com.hk) (www.sse.com.cn)
(www.junshipharma.com)
81
2012
2018 12 2020 7
(GMP)
TopAlliance Fc
82
2020
2020 1,003
2020 30 28 2
15.95 2019 106%
FDA
FDA PD-1
FDA
etesevimab JS016
Ib/II etesevimab
etesevimab 1,400 mg bamlanivimab 700 mg FDA
PD-1
PD-1
83
2020
2020 1 2019
2019
2020 7
2019 TOP20
2020 8 2020
2020 8 2020
2020
2020 9 JS016 22 CIIF
2020 10 (CHS 2020) 2020
2020 11 (BioCentury-BayHelix China Healthcare Summit)
BayHelix Awards 2020 “R&D Achievement of the Year” 2020
E 2020 100
84
2020 12 2020
2019
2020 12 100
2020
2021 1 2020 2020
2021 1
IR
2021 1 2020
85
2020
2020
(HR Technology Conference & Exposition)
86
2020 5
JS016 2020
6 JS016 2020 9
JS016 22 CIIF
JS016 etesevimab bamlanivimab
JS016
87
2020 2 21 23
100
17,754 475,073
2020 1 100
88
89
17
1.
90
2.
91
3.
1
2
3
6
5 4
7
9 8
10
11
13
12
15
16
17
14
92
2020
1.
2020
2020
2.
2020
2020
CMD CMD
93
2020
3.
(www.hkex.com.hk) (www.sse.com.cn)
(www.junshipharma.com)
94
4.
95
(ADC)
1.
2020
1,778 2019 87.9%
96
2020
97
7
98
Anwita Biosciences, Inc.
2020
Revitope Oncology Inc.
license-in
IL-2
CD39
PARP
JS016
Coherus
EUA
JS016 EUA XPO1/AuroraA/
EGFR exon 20/EGFR 4th
>900
~300
~1,500
>1,100
Trop2 -
Tub196
CDK/PI3K
Anwita IL-21
/Anti-HSA-IL-2N
Revitope T
99
2.
2020
21 30
2020 2 BTLA (TAB004/JS004) NMPA
2020 4
2020 5 IL-17A (JS005) I
2020 6 III
2020 7 ADC Trop2 Tub196 DAC-002(JS108)
NMPA 11
2020 9 III
2020 9
III 2020 12
III
100
2020
2020 4 NMPA
2021 2 NMPA
2020 5 NMPA
7
NMPA
FDA
2020 3 FDA
2020 5 FDA 9 FDA
FDA PD-1
9 FDA
2021 2
2020 12 PD-1
PD-1
101
2020
1 8 9
Cancer Communications, IF 5.627 CSCO 2020 JAMA Network Open, IF 5.032
10
SITC 2020
2 7
ASCO-GU
ESMO 2020
11
ESMO ASIA 2020
3 6
Clinical Cancer Research, IF 10.107 ASCO 2020 12
WCLC 2020
4 5 13
AACR 2020 Nature IF 42.778 Journal of Clinical Oncology, IF 32.956
2020
ASCO ASCO (ASCO-GU) (ESMO
2020) (AACR 2020) (STIC 2020)
(CSCO 2020)
102
ASCO
2020 5 29 31 (ASCO 2020) 9
Ib
2
6,300
ASCO
CSCO
2020 5 31 ASCO
CSCO
CSCO 2020ASCO
STIC
2020 11 9 14 35 (SITC 2020)
R0 100% 58.3%
(MPR) 16.7% (pCR) 4.5
CSCO
2020 12 29 CSCO
103
3.
2020 12 31 70 55 15
104
1.
105
GMP
2020 5,000
100%
2020
(EQS) (DMS) (TMS) (QMS)
(LIMS) 2020
(TMS) (DMS)
(DCS) (MES)
2020 10 2 1
1 GMP 1 QP
5
106
2.
(GSP)
2020 12 31
300 1,500 1,100
107
3.
2021 1 2020
108
2020
109
1.
2020 61,578.49
33,918.49 27,660.00
45%
55%
2020 (BMS)
110
2.
2020
2020
111
112
3.
1.
2.
5. 3.
4.
113
1.
2020
114
2020
2020
2,453 50%
2%
50% 47%
50%
51%
0.65% 15 7 6
6 4 4 2
1
2020
115
2020
2021
2020
70.73% 69.14% 2020
6.6 27
2020
2020
2020
116
2020
GMP
2020 2020 11 19
117
2020
118
2020 11 28
2020 9
119
2.
2020
2020
120
2020 1 9 10 15
2020 1
2020 2
2019
A1.1 1
NOX 4.96 3.82
SOX 0.004 0.002
4.96 3.82
0.003 0.005
A1.2
1 3
5,783.59 3,812.70
2 4
23,861.66 13,007.78
29,645.25 16,820.48
1& 2 18.59 21.70
1
2019
2
2019 2020 2020
2019
3
4
121
2020 2
2019
A1.3
137.27 63.65
0.09 0.08
A1.4
183.005 615.00
0.11 0.79
A2.1
33,918.49 18,490.09
6
27,660.00 18,227.66
61,578.49 36,717.75
38.61 47.37
A2.2
303,598.00 194,273.00
190.36 250.65
5
2019 2020
2019
6
122
2020 2
2019
A2.5
17.04 10.95
14.39 9.81
31.44 20.76
0.02 0.03
B1.1
2020 2019
2,453 1,421
1,230 738
1,223 683
2,453 1,357
0 29
0 35
≤30 1,144 596
30~50 1,249 759
≥50 60 66
2,437 1,410
16 11
B1.2
24.39% 16.71%
19.41% 18.14%
≤30 19.66% 15.80%
30~50 24.60% 19.61%
≥50 11.11% 8.20%
22.04%
7.41%
123
2020 2019
B2.1
B2.2
1367
B3.1
70.57% 73.58%
70.07% 68.52%
53.21% 38.00%
74.51% 50.18%
70.73% 79.89%
B3.2 8
27.72 72.69
26.86 68.75
15.28 35.70
18.26 49.62
30.59 80.21
B7.1
7
2020 136
8
2020
2020 2019
124
A A1
2.
(a)
(b)
A1.1
A1.2
1 2
A1.3
A1.4
A1.5
2.
A1.6
2.
125
A2
1.
A2.1
A2.2
A2.3
1.
A2.4
1.
A2.5
126
A3
1.
A3.1
1.
A4
3.
A4.1
3.
B B1
1.
(a)
(b)
B1.1
B1.2
127
B2
1.
(a)
(b)
B2.1
B2.2
B2.3
1.
B3
1.
B3.1
B3.2
B4
1.
(a)
(b)
128
B4.1
1.
B4.2
1.
B5
3.
B5.1
B5.2
3.
B5.3
3.
B5.4
3.
129
B6
1.
2.
(a)
(b)
B6.1
B6.2
B6.3
3.
B6.4
1.
2.
B6.5
2.
130
B7
1.
(a)
(b)
B7.1
1.
B7.2
1.
B7.3
2.
B8
2.
B8.1
2.
B8.2
2.
131
30 28 2
35
32 42
172 173
132
A
2020 7 15 A 55.50
87,130,000 A 4,836 A 1.00
A 51.61
4,497
A A 2020 6 19
2020
A 4,645,421 A
2020 5 27 2020 7 1 2020 5 27
2020 5 8 2020 7 15 A
18A.09 18A.11
H 2018 12 24 18A
8.05(3) 18A.12
2020 7 9 18A.09 18A.11
2020 7 15 B
2020 7 10 2020 7 13
133
JS001
2021 2
NMPA
2021 2
NMPA
2021 3 FDA BLA
FDA (Rolling Review) FDA BLA PD-1
2021 3 NMPA
JS103
2021 3 NMPA JS103
TIGIT TAB006/JS006
2021 1 TAB006/JS006 NMPA 2021 2 TAB006/JS006 FDA
TAB006/
JS006
PD-1/TGF- JS201
2021 2 NMPA JS201
134
Etesevimab JS016/LY-CoV016
2021 2 FDA etesevimab 1,400mg
bamlanivimab 700mg COVID-19
COVID-19
2021 2
Coherus
Coherus
Coherus JS006 TIGIT JS018-1 IL-2 2
11.1
Coherus
20% Coherus
Coherus
2021 2 A H H (1877.HK)
A (688180.
SH) 50 2021 3 15
40
135
H
H H 3,003
2020 12 31 107 H
2019 8 29 2019
2020 8 28 H
2019 2020
2020 2020
2019 12 31 2020 6 30 12 31 12 31
3
1,952,203 65% 2,162,440 72% 2,372,677 79% 2,270,018 102,659 2021 12 31
1,201,356 40% 1,201,356 40% 1,291,457 43% 1,247,302 44,155 2021 12 31
JS001
480,542 16% 480,542 16% 600,678 20% 553,596 47,082 2021 12 31
JS004 1a
270,305 9% 480,542 16% 480,542 16% 469,120 11,422 2021 12 31
1b
750,847 25% 540,610 18% 330,373 11% 325,802 4,571 2022 12 31
1c
300,339 10% 300,339 10% 300,339 10% 334,545 71 2021 12 31
2 2
2,930,365
3,003,389 100% 3,003,389 100% 3,003,389 100% 2
107,301
136
1. 2019 2019 8
a.
b.
c.
2. 34
3.
4.
[2020]940 2020 7 A
8,713 A 55.50 4,836
339 4,497 A
2020 6 22 A
2020 2020
12 31 12 31
1,200,000 474,780 725,220 2023 12 31
700,000 700,000 – 2020 12 31
800,000 529,267 270,733 2023 12 31
1,796,978 362,239 1,434,739 2023 12 31
4,496,978 2,066,286 2,430,692
137
JS001 PD-1 (TUOYI)
(JS001)
1
2019
2
2020
1,778
88%
138
3
PD-1 PD-1
4
2020
2020 PD-1
139
5
4+7
UBP1211 JS501 28
6
2020
(i) 11.56% 2019 10.04% 34.45% 2019
33.40%
(ii) 33.45% 2019 20.99% 79.89% 2019
64.40%
5%
140
14
2020 12 31 35
30
2020 12 31 872,496,000 689,749,500 A 182,746,500 H
A 2020 7 15
87,130,000 A
A A 2020 11 2
2018
1,219,500 A 2018
2020 12 31
2020 12 31 25
141
2018
2018 5 14 2018
2019 6 17 2018 2019
2019 H 2019 5
27 2018
2020 5 11 2019 2020 2020
H 2020 4 20
2018 3 12 268 6,023,000
2018
2018
2018
(a)
2018
2018
12
2018
(b) 2018
2018
142
(c) 2018
2022 12 14 29
(d)
2018
(e) 9.2
2018
(f) 2018
25%
12 5
35% 5
17 40%
17 29
(g)
H 2018
143
2020 8 28 2018
203 1,219,500 A
9.2 2020 11 2 2018
1,219,500 A 2020 12 31 0.14%
203 11,219,400 1,219,500 9,999,900
A
2018
2020 8 28 2020 11 2
2020 12 31 3,666,700 204 3,666,700
A 2020 12 31 0.42% 2018 3
1,136,800 A
1,136,800
2020 2020
1 1 (2)
12 31 (1)
A
10,000 – 2,500 – – 7,500 2019 3 12 9.2
2022 12 14
5,203,000 – 1,217,000 – 326,800 3,659,200 2019 3 12 9.2
2022 12 14
5,213,000 – 1,219,500 – 326,800 3,666,700
1. 25% 12
5 35%
5 17
40% 17
29
2.
144
2021 12 31 2020 12 31
A
2021 12 31
A
A
2021 12 31 3,666,700 3,666,700 0.42%
A 2018
2018
32
2018
2020 A
2020 9 29 2020 A 2020 A
2020 11 16 2020 2020 A 2020 H
2020 A
2020 A
(a) 2020 A
145
(b) 2020 11 16 2020 A
1,933 28,519,000
(c) 2020 A 2020
11 16 2020 2020 A 2020 H
12 12
(d) 2020 A 35,648,000 A
A 5.17% 4.09% 2020 A
7,129,000
A 20%
A
(e) 1%
(f) 2020 A 2020 11 16
48
(g)
(1) 40% 12
24 (2)
30% 24 36
(3) 30% 36
48
146
(1) 50% 12
24 (2)
50% 24 36
(h) A 55.50
A A 55.50
(i) 2020 A A 2020 9
29 A 50% A 85.46 (ii) 20 60
120 A 50% 20 A 90.25
A 2020 7 15 A 55.50
(i) 2020 A
(j)
147
2020 12 31 28,519,000 2020 11 16
2020
11 16 2020
(1)
12 31 (2)
(3)
820,000 – – – 820,000 2021 11 16
(5)
2024 11 15
1,560,000 – – – 1,560,000 2021 11 16
(5)
2024 11 15
820,000 – – – 820,000 2021 11 16
(5)
2024 11 15
2,000,000 – – – 2,000,000 2021 11 16
(5)
2024 11 15
820,000 – – – 820,000 2021 11 16
(5)
2024 11 15
270,000 – – – 270,000 2021 11 16
2024 11 15
360,000 – – – 360,000 2021 11 16
2024 11 15
300,000 – – – 300,000 2021 11 16
2024 11 15
300,000 – – – 300,000 2021 11 16
2024 11 15
150,000 – – – 150,000 2021 11 16
2024 11 15
80,000 – – – 80,000 2021 11 16
2024 11 15
80,000 – – – 80,000 2021 11 16
2024 11 15
80,000 – – – 80,000 2021 11 16
2024 11 15
148
2020
11 16 2020
(1)
12 31 (2)
(3)
30,000 – – – 30,000 2021 11 16
(6)
2024 11 15
20,849,000 – – – 20,849,000 2021 11 16
2024 11 15
1,919
28,519,000 – – – 28,519,000 2021 11 16
2024 11 15
(1) 2020 11 16
(2) (1) 40% 12
24 (2) 30%
24 36 (3)
30% 36 48
(1) 50% 12
24 (2) 50%
24 36
(3) 7,129,000
(4) A 55.50
(5) 14A
(6) 14A
(7)
32
2020 A 2020 10 22
2020 11 16
149
2020 A
2020 10 14
2020 6 19
2020 11 16
Roy Steven Herbst
2020 6 19
2020 11 16
2020 11 16
2020 11 16
13.51(2) (a) (e) (g)
150
2020 2021
3 30
Roy Steven Herbst 2020
2021
3 30 2020
151
3.13
3.13
2020 6 19 2020 4 24
600100
2018
2020 4 27
2020 11 16 2020 4 26
2020 4 27
152
12
2020 12 31 XV
XV 7 8
352
(1)
(%)(1) (%)(1)
(2)
A 88,072,968 (L) 12.77% 10.09%
H 2,600 (L) 0.00% 0.00%
(2)
A 129,978,568 (L) 18.84% 14.90%
(3)
A 1,560,000 (L) 0.23% 0.18%
(4)
A 13,960,000 (L) 2.02% 1.60%
(5)
A 9,428,000 (L) 1.37% 1.08%
(6)
A 2,000,000 (L) 0.29% 0.23%
A 3,657,600 (L) 0.53% 0.42%
A 7,774,500 (L) 1.13% 0.89%
(7)
A 196,370,736 (L) 28.47% 22.51%
H 2,600 (L) 0.00% 0.00%
(8)
A 78,852,000 (L) 11.43% 9.04%
H 37,189,000 (L) 20.35% 4.26%
(8)
153
1. L S P 2020 12 31
872,496,000 689,749,500 A 182,746,500 H
2. 2020 12 31 87,252,968 A 2,600 H 2020 A
820,000
(i)
2017 12 25 2017
2020 12 31 2017 108,297,768
A 41,060,000 A (ii)
2019 7 26 2019 2020 12 31
2019 21,680,800 A
2020 12 31 (i) 20% 4,372,144
A 2017 (ii)
40%
4,600,000 43,584,000 A 2017 86.28%
52,556,144 A
3. 2020 12 31 2020 A 1,560,000
4. 2020 12 31 13,140,000 A 2020 A 820,000
5. 2020 12 31 8,608,000 A 2020 A
820,000
6. 2020 12 31 2020 A 2,000,000
7. 2020 12 31 7,774,500 A 60%
86.28%
2017
154
8. 2020 12 31 76,590,000 A
2,262,000 A
99.99%
2020 12 31 Loyal Valley Capital Advantage Fund LP LVC Fund I Loyal Valley Capital Advantage Fund
II LP LVC Fund II LVC Renaissance Fund LP LVC Renaissance Fund LVC Fund I LVC Fund II
LVC Funds 10,106,000 H 12,127,000 H 14,956,000 H Loyal Valley Capital
Advantage Fund GP Limited LVC Fund I GP LVC Fund I Loyal Valley Capital Advantage Fund
II Limited LVC Fund II GP LVC Fund II LVC Renaissance Limited LVC Renaissance GP
LVC Renaissance Fund LVC Fund I GP LVC Fund II GP LVC Renaissance GP LVC Holdings
Limited LVC Innovate Limited LVC Bytes Limited Jovial Champion
Investments Limited Jovial Champion Investments Limited Vistra Trust (Singapore) Pte.
Limited LVC Renaissance Fund(i) Golden Valley Global Limited 20.13%
99.99%
(ii) Loyal Valley Innovation Capital (HK) Limited
33.28% LVC Funds
37,189,000 H
2020 12 31
XV 352
XV
155
2020 12 31
XV 2 3
336
(1)
(%)(2) (%)(2)
(3) (4)
A 41,060,000 (L) 5.95% 4.71%
A 155,310,736 (L) 22.52% 17.80%
A 43,584,000 (L) 6.32% 5.00%
(4)
A 152,786,736 (L) 22.15% 17.51%
A 4,600,000 (L) 0.67% 0.53%
(4)
A 191,770,736 (L) 27.80% 21.98%
(4)
A 4,372,144 (L) 0.63% 0.50%
A 191,998,592 (L) 27.84% 22.01%
(4)
A 4,288,400 (L) 0.62% 0.49%
A 192,082,336 (L) 27.85% 22.02%
(4)
A 3,789,720 (L) 0.55% 0.43%
A 192,581,016 (L) 27.92% 22.07%
(4)
A 3,719,504 (L) 0.54% 0.43%
A 192,651,232 (L) 27.93% 22.08%
(4)
A 2,884,000 (L) 0.42% 0.33%
A 193,486,736 (L) 28.05% 22.18%
(5)
A 21,680,800 (L) 3.14% 2.48%
A 88,072,968 (L) 12.77% 10.09%
(6)
A 76,590,000 (L) 11.10% 8.78%
(6)
A 76,590,000 (L) 11.10% 8.78%
(6)
A 76,590,000 (L) 11.10% 8.78%
(6)
A 78,852,000 (L) 11.43% 9.04%
156
(1)
(%)(2) (%)(2)
A 78,852,000 (L) 11.43% 9.04%
(6)(8)
(7)(8)
H 37,189,000 (L) 20.35% 4.26%
Loyal Valley Capital Advantage H 10,106,000 (L) 5.53% 1.16%
Fund LP (7)(9)
Loyal Valley Capital Advantage H 10,106,000 (L) 5.53% 1.16%
Fund GP Limited (7)
Loyal Valley Capital Advantage H 12,127,000 (L) 6.64% 1.39%
Fund II LP (7)(10)
Loyal Valley Capital Advantage H 12,127,000 (L) 6.64% 1.39%
Fund II Limited (7)
LVC Renaissance Fund LP(7) H 14,956,000 (L) 8.18% 1.71%
LVC Renaissance Limited (7)
H 14,956,000 (L) 8.18% 1.71%
LVC Holdings Limited(7) H 22,233,000 (L) 12.17% 2.55%
LVC Management Holdings Limited(7) H 22,233,000 (L) 12.17% 2.55%
LVC Bytes Limited LVC H 37,189,000 (L) 20.35% 4.26%
Innovate Limited (7)
Jovial Champion Investments Limited(7) H 37,189,000 (L) 20.35% 4.26%
Vistra Trust (Singapore) Pte. Limited (7)
H 37,189,000 (L) 20.35% 4.26%
(9)
H 10,106,000 (L) 5.53% 1.16%
Eminent Azure Limited (9)
H 10,106,000 (L) 5.53% 1.16%
Prosperous Wealth Global Limited(9) H 10,106,000 (L) 5.53% 1.16%
Highbury Investment Pte Ltd (10)
H 15,226,289 (L) 8.33% 1.75%
H 12,127,000 (L) 6.64% 1.39%
157
(1)
(%)(2) (%)(2)
GIC (Ventures) Pte. Ltd. (10)
H 27,353,289 (L) 14.97% 3.14%
GIC Special Investments H 27,353,289 (L) 14.97% 3.14%
Private Limited (10)
GIC Private Limited(10) H 27,053,289 (L) 14.80% 3.10%
H 1,933,311 (L) 1.06% 0.22%
H 13,339,000 (L) 7.30% 1.53%
H 13,339,000 (L) 7.30% 1.53%
Gaoling Fund, L.P. (11)
H 10,715,000 (L) 5.86% 1.23%
Hillhouse Capital Advisors, Ltd. (11)
H 11,400,000 (L) 6.24% 1.31%
(12)
H 9,271,700 (L) 5.07% 1.06%
1. L S P
2. 2020 12 31 872,496,000 689,749,500 A 182,746,500 H
3. 2020 12 31 41,060,000 A 2017
2017 155,310,736 A
87,252,968 A 2020 A 820,000
4. 2017 2017
A
5. 2019 2019
6. 2020 12 31 76,590,000 A
99.99%
76,590,000 A
2,262,000 A
A
158
7. 2020 12 31 Loyal Valley Capital Advantage Fund LP LVC Fund I Loyal Valley Capital Advantage Fund
II LP LVC Fund II LVC Renaissance Fund LP LVC Renaissance Fund LVC Fund I LVC Fund II
LVC Funds 10,106,000 H 12,127,000 H 14,956,000 H Loyal Valley Capital
Advantage Fund GP Limited LVC Fund I GP LVC Fund I H
Loyal Valley Capital Advantage Fund II Limited LVC Fund II GP LVC Fund II
H LVC Renaissance Limited LVC Renaissance GP LVC Renaissance Fund
H
LVC Fund I GP LVC Fund II GP LVC Holdings Limited LVC Management Holdings Limited
LVC Holdings Limited LVC Management Holdings Limited LVC Fund I LVC Fund II
H
LVC Fund I GP LVC Fund II GP LVC Renaissance GP LVC Innovate Limited LVC Bytes Limited
LVC Innovate Limited Jovial Champion Investments Limited Vistra Trust (Singapore)
Pte. Limited LVC Innovate Limited LVC Bytes Limited Jovial Champion
Investments Limited Vistra Trust (Singapore) Pte. Limited LVC Funds H
8. 2020 12 31
76,590,000 A
2,262,000 A
9. 2020 12 31 Eminent Azure Limited Prosperous Wealth Global Limited
LVC Fund I 33.34% LVC Fund I 10,106,000
H
10. 2020 12 31 Highbury Investment Pte Ltd Highbury 15,226,289 H Highbury LVC
Fund II 90.90% LVC Fund II 12,127,000 H Highbury GIC (Ventures) Pte. Ltd.
GIC Ventures GIC Special Investments Private Limited GIC SIPL
GIC Private Limited GIC Private GIC Ventures GIC SIPL GIC
Private Highbury H
11. 2020 12 31 Hillhouse Capital Advisors, Ltd. Gaoling Fund, L.P. YHG Investment, L.P.
Gaoling Fund, L.P. YHG Investment, L.P. 10,715,000 H 685,000 H
12. 2020 12 31 CICC
CICC Financial Trading Limited CICC 8,871,700 H 400,000 H
159
(a) 2020 7 15 87,130,000 A A
(b) A A 2020 11 2
2018
1,219,500 A 2018
(c) 2020 11 16 2020 A 28,519,000
2020 A
A 2020 7 15
A 55.50 87,130,000 A
2020 6 19 2020
1
A
CICC
A 55.50 A 4,645,421
A 259,110,000 A
2020 7 15 12
160
A (1)
(2)
10,500,000 4.05% 188,100
(2)
46,130,000 17.80% 826,900
(2)
10,500,000 4.05% 188,100
(2)
10,500,000 4.05% 188,100
77,630,000 29.95% 1,391,200
181,480,000 70.04% 3,254,221
259,110,000 100% 4,645,421
1. A A
2.
3.
161
2020 5 27 2020 7 1 2020 5 27
2020 A
2020 A 2020 A 2020 11
16 2020 2020 A 2020 H
2020 11 16 A 55.50 1,933
14A
2020 A
2020 A
2020 A 2020
10 22 2020 11 16
60%
40%
2020 1 9
162
2018 12 4
2018 12 24
2020 12 31
2020 20,000,000
2020 1 9
14A.101 14A
163
14A.105
2020 12 31
2020 1 9
2020 1 1 9
34
34 14A.76 14A.95
14
53
H
20%
20%
164
H
[2008]897 H 2008 10%
2020 H
62 78
2020
165
2020
79 130
166
8.08(1)
H
(a) 16%
(b) H
(c) H
2018 A
(i) 18A.07 H
375 (ii)
15.71%
8
167
2020 12 31
2020 12 31
H
2021 6 29 H
H 2021 6 21 2021 6 29 H
H 2021 6 18
H 183 54
2021 3 30
*
168
*
172 273
2020 12 31
2020 12 31
169
2020 12
31 1,778,023,000
24 2020 12 31
215,933,000
170
171
2021 3 30
172
2020 12 31
12 31
2020 2019
5 1,594,897 775,089
(372,531) (90,684)
1,222,366 684,405
6 77,454 60,768
7 27,591 21,222
(255) 1,038
(1,778,023) (946,100)
(687,971) (320,056)
(443,346) (216,889)
(1) (5)
(3,804) (2,522)
(54,081) (31,685)
8 (29,391) (13,300)
9 (1,669,461) (763,124)
10 3,822 18,891
(1,665,639) (744,233)
(21,928) 3,178
(1,687,567) (741,055)
173
2020 12 31
12 31
2020 2019
(1,665,639) (743,922)
– (311)
(1,665,639) (744,233)
(1,687,567) (740,744)
– (311)
(1,687,567) (741,055)
11
(2.02) (0.95)
(2.02) (0.95)
174
2020 12 31
12 31
2020 2019
14 2,348,155 1,827,868
15 186,239 179,518
16 31,019 6,291
17 1,021 1,022
18 65,150 71,224
29 26,113 20,590
21 297,725 335,466
22 356,725 69,345
3,312,147 2,511,324
19 343,425 180,666
20 663,323 157,416
21 306,954 352,163
22 17 17
23 – 6,828
23 3,384,998 1,214,026
4,698,717 1,911,116
24 1,215,016 514,639
25 252,346 76,891
28 25,220 13,846
1,492,582 605,376
3,206,135 1,305,740
6,518,282 3,817,064
175
2020 12 31
12 31
2020 2019
25 542,222 744,896
27 103,809 56,320
28 30,991 27,332
677,022 828,548
5,841,260 2,988,516
30 872,496 784,147
4,968,767 2,204,372
5,841,263 2,988,519
(3) (3)
5,841,260 2,988,516
172 273 2021 3 30
176
2020 12 31
2019 1 1 760,310 3,775,539 – 21,700 (9,367) 9,357 (1,235,293) 3,322,246 (1,113) 3,321,133
– – – – – – (743,922) (743,922) (311) (744,233)
– – – – – 3,178 – 3,178 – 3,178
– – – – – 3,178 (743,922) (740,744) (311) (741,055)
H 30 23,837 380,001 – – – – – 403,838 – 403,838
H – (12,146) – – – – – (12,146) – (12,146)
32 – – – 15,638 – – – 15,638 – 15,638
– – – – 9,367 – (9,367) – – –
– – – – – – (313) (313) 313 –
– – – – – – – – 1,108 1,108
2019 12 31 784,147 4,143,394 – 37,338 – 12,535 (1,988,895) 2,988,519 (3) 2,988,516
– – – – – – (1,665,639) (1,665,639) – (1,665,639)
– – – – – (21,928) – (21,928) – (21,928)
– – – – – (21,928) (1,665,639) (1,687,567) – (1,687,567)
177
2020 12 31
A 30 87,130 4,748,585 – – – – – 4,835,715 – 4,835,715
A – (338,737) – – – – – (338,737) – (338,737)
32 – – – 6,549 – – – 6,549 – 6,549
1,219 21,110 – (11,110) – – – 11,219 – 11,219
32 – – 25,565 – – – – 25,565 – 25,565
2020 12 31 872,496 8,574,352 25,565 32,777 – (9,393) (3,654,534) 5,841,263 (3) 5,841,260
9
178
2020 12 31
12 31
2020 2019
(1,669,461) (763,124)
(20,278) (29,222)
29,391 13,300
(1,798) (599)
31,222 7,700
(43,594) (700)
– (23,426)
(630) –
120,581 41,452
28,745 17,068
2,036 1,071
255 (1,038)
4,227 –
734 638
30,728 11,797
1 5
3,804 2,522
(1,484,037) (722,556)
(166,986) (132,198)
(512,646) (157,505)
(3,660) (328,230)
658,446 150,664
– (1,111)
11,778 4,313
(1,497,105) (1,186,623)
(1,701) (411)
(1,498,806) (1,187,034)
179
2020 12 31
12 31
2020 2019
20,278 29,222
(560,581) (791,585)
(26,718) (4,592)
(5,383) (66,972)
(3,552) (881)
851 –
– (23,310)
6,828 16,482
18 – (73,746)
18 2,900 –
(175,137) (117,346)
106 72,200
9,443 17,712
(70,029) –
70,029 –
(4,520) (16,827)
– 54
37,509 7,559
(697,976) (952,030)
180
2020 12 31
12 31
2020 2019
– (200,000)
H – 403,838
H – (26,307)
A 4,835,715 –
A (337,730) (1,410)
374,239 1,681,516
(401,416) (1,189,137)
(46,236) (60,759)
(22,269) (15,267)
– 1,108
11,219 –
4,413,522 593,582
2,216,740 (1,545,482)
1,214,026 2,763,570
(45,768) (4,062)
3,384,998 1,214,026
181
2020 12 31
1.
* 2012 12 27
2015 5 2015 8
833330) 2018 12 24 H
1877) 2020 5 8
2020 7 15 A 688180)
2.
2020 1 1
1 8
3
9 39 7
16 COVID-19
182
2020 12 31
2.
1 8
1 8
16 COVID-19
COVID-19 COVID-19
2021 6 30
16
2020 1 1
183
2020 12 31
2.
17 1
3 2
9 39 4
7 4
16
10
28 3
1 1
1 1
2
8 1
16 2
37 2
2018 2020 2
1
2023 1 1
2
2022 1 1
3
4
2021 1 1
184
2020 12 31
2.
1
12
(i) 12
(ii)
32
2020 12 31
3.
3.1
185
2020 12 31
3.
3.1
2
16
2
36
186
2020 12 31
3.
3.2
187
2020 12 31
3.
3.2
(i) (ii)
188
2020 12 31
3.
3.2
9
28
36
36
189
2020 12 31
3.
3.2
9
190
2020 12 31
3.
3.2
(a)
191
2020 12 31
3.
3.2
(b)
(c)
192
2020 12 31
3.
3.2
16
193
2020 12 31
3.
3.2
12
194
2020 12 31
3.
3.2
9
195
2020 12 31
3.
3.2
196
2020 12 31
3.
3.2
197
2020 12 31
3.
3.2
198
2020 12 31
3.
3.2
199
2020 12 31
3.
3.2
12
200
2020 12 31
3.
3.2
201
2020 12 31
3.
3.2
202
2020 12 31
3.
3.2
203
2020 12 31
3.
3.2
204
2020 12 31
3.
3.2
15
3
205
2020 12 31
3.
3.2
(i)
(ii)
206
2020 12 31
3.
3.2
9
9
(i)
207
2020 12 31
3.
3.2
9
(i)
30
(ii)
90
208
2020 12 31
3.
3.2
9
(iii)
(iv)
(v)
209
2020 12 31
3.
3.2
9
(v)
210
2020 12 31
3.
3.2
(i)
9
211
2020 12 31
3.
3.2
(i)
(ii)
9
212
2020 12 31
4.
3
2020 12 31
26,113,000 2019 20,590,000
386,314,000 2019 37,599,000
3,529,965,000 2019 1,975,441,000
213
2020 12 31
4.
2020 12 31 172,127,000 2019 18,000,000
37b
37b 20
5.
2020 2019
1,102,278 774,124
405,103 –
87,516 965
1,594,897 775,089
214
2020 12 31
5.
35 65 2019 35 45
15
2020 12 31
2020
12 31 10,000,000 70,956,000
50,000,000 334,147,000
195,000,000 2020 12 31
2020 12 31
12,378,000
87,232,000
2020 12 31 2020 12 31
87,516,000 2019 965,000 60 2019
90
15
215
2020 12 31
5.
12 31 12 31
2020 2019 2020 2019
1,594,897 775,089 2,902,608 2,407,578
– – 13,947 5,227
1,594,897 775,089 2,916,555 2,412,805
10%
12 31
2020 2019
A1 2
85,246
B 3
591,433 –
1
2
10%
3
216
2020 12 31
6.
12 31
2020 2019
20,278 29,222
a 1,798 599
b 16,758 30,947
c 38,504 –
116 –
77,454 60,768
(a)
(b)
(c)
217
2020 12 31
7.
12 31
2020 2019
43,594 700
630 –
(734) (638)
(11,672) (2,266)
(4,227) –
– 13,520
– 9,906
27,591 21,222
8.
12 31
2020 2019
43,115 31,423
(16,803) (20,412)
26,312 11,011
3,079 2,289
29,391 13,300
5.23% 2019 5.23%
218
2020 12 31
9.
12 31
2020 2019
3,080 2,400
2,036 1,071
32,240 20,563
(3,495) (3,495)
28,745 17,068
133,583 41,684
(13,002) (232)
120,581 41,452
52,979 27,340
151,942 89,735
310,623 130,676
860,104 437,175
28,152 39,827
32,114 15,638
(27,357) (39,167)
(53,046) (10,755)
839,967 442,718
219
2020 12 31
10.
12 31
2020 2019
1,695 –
6 411
1,701 411
29 (5,523) (19,302)
(3,822) (18,891)
25%
2020 11 18 2018 11 2
2020 2023 2018 2021
15%
15%
2017 2017
21%
2020 12 31
8.84% 2019 8.84%
2019 12 31
220
2020 12 31
10.
12 31
2020 2019
(1,669,461) (763,124)
25% 2019 25% (417,365) (190,781)
– 1
951 631
61,051 108,597
(138,825) (103,478)
87,179 3,666
– (5,892)
6 411
391,851 219,575
– (51,621)
11,330 –
(3,822) (18,891)
[2018]99
2019
2020 12 31 175% 2019 175%
221
2020 12 31
11.
(a)
12 31
2020 2019
(1,665,639) (743,922)
12 31
2020 2019
824,816,637 783,624,056
(b)
32 2018 5 14 2020 11 16
2020 12 31
2019 12 31
222
2020 12 31
12.
j
2020 12 31
– 7,637 17,990 18 1,415 27,060
– 4,966 2,541 67 744 8,318
– 3,046 1,350 27 744 5,167
– 3,757 1,401 68 744 5,970
– 3,106 1,350 – 1,814 6,270
a – 2,015 33,415 – – 35,430
– – – – – –
– – – – – –
– – – – – –
– – – – – –
a – – – – – –
– – – – – –
– – – – – –
b – 197 250 17 – 464
– 240 199 30 – 469
– – – – – –
d – 211 – – – 211
5,431 – – – – 5,431
e 118 – – – – 118
f – – – – – –
200 – – – – 200
Roy Steven Herbst 2,025 – – – – 2,025
g 42 – – – – 42
h 106 – – – – 106
7,922 25,175 58,496 227 5,461 97,281
223
2020 12 31
12.
j
2019 12 31
– 6,809 660 3 – 7,472
– 3,672 720 103 – 4,495
– 2,997 692 24 – 3,713
– 2,731 600 103 – 3,434
– 2,768 692 – – 3,460
– 2,768 692 – – 3,460
– – – – – –
– – – – – –
– – – – – –
– – – – – –
i – 139 35 29 166 369
i – 165 160 36 199 560
– – – – – –
i – – – – – –
– – – – – –
b – 82 – 27 – 109
b – 125 – 35 – 160
c – – – – – –
5,536 – – – – 5,536
266 – – – – 266
200 – – – – 200
200 – – – – 200
Roy Steven Herbst 2,076 – – – – 2,076
8,278 22,256 4,251 360 365 35,510
224
2020 12 31
12.
(a) 2020 10
(b) 2019 5 2020 11
(c) 2019 6
(d) 2020 11
(e) 2020 6
(f) 2020 11
(g) 2020 11
(h) 2020 6
(i) 2019 4
(j) 2020 2019 12 31
225
2020 12 31
12.
2019
2019
12 31
2020 2019
1,811 –
5,900 –
34 –
7,745 –
12 31
2020 2019
3,500,001 4,000,000 – 1
4,000,001 4,500,000 – 1
5,000,001 5,500,000 – 1
6,000,001 6,500,000 – 1
7,000,001 7,500,000 1 –
8,000,001 8,500,000 – 1
8,500,001 9,000,000 1 –
9,500,001 10,000,000 1 –
31,000,001 31,500,000 1 –
40,500,001 41,000,000 1 –
13.
2020 2019 12 31
226
2020 12 31
14.
2019 1 1 65,548 183,286 52,187 20,421 4,573 676,860 1,002,875
12,752 11,974 48,769 7,938 9,624 839,837 930,894
728 15,288 10,487 – – (26,503) –
– (40) (1,579) (214) – – (1,833)
– – (84) – – (1) (85)
2019 12 31 79,028 210,508 109,780 28,145 14,197 1,490,193 1,931,851
102,635 6,038 38,644 1,029 12,338 493,866 654,550
704,785 699,860 156,842 5,224 – (1,566,711) –
– (2,133) (670) – – – (2,803)
– – 161 – – – 161
2020 12 31 886,448 914,273 304,757 34,398 26,535 417,348 2,583,759
2019 1 1 3,478 28,161 23,078 7,070 1,747 – 63,534
3,422 17,951 12,670 4,425 3,216 – 41,684
– (26) (930) (192) – – (1,148)
– – (87) – – – (87)
2019 12 31 6,900 46,086 34,731 11,303 4,963 – 103,983
28,085 57,829 34,260 5,073 8,336 – 133,583
– (1,622) (447) – – – (2,069)
– – 107 – – – 107
2020 12 31 34,985 102,293 68,651 16,376 13,299 – 235,604
2020 12 31 851,463 811,980 236,106 18,022 13,236 417,348 2,348,155
2019 12 31 72,128 164,422 75,049 16,842 9,234 1,490,193 1,827,868
227
2020 12 31
14.
4.75%
9.50% 31.67%
19.00% 31.67%
19.00% 31.67%
33.33% 50.00%
2020 12 31 1,716,673,000 2019 1,607,916,000
25
96,491,000 2019
15.
2020 12 31
131,069 55,170 186,239
2019 12 31
136,628 42,890 179,518
2020 12 31
5,559 26,681 32,240
(3,495) – (3,495)
2,064 26,681 28,745
2019 12 31
4,752 15,811 20,563
(3,495) – (3,495)
1,257 15,811 17,068
228
2020 12 31
15.
12 31
2020 2019
IFRS 16 12
7,441 5,159
151 647
38,323 90,334
38,961 76,949
20 50
2019
2020 2019 12 31
2020 12 31 58,862,000 2019 62,425,000
25
2020 12 31
1 3 2019 1 5 37,280,000 2019
10,997,000
28 37b
229
2020 12 31
16.
2019 1 1 1,632 – – 1,632
5,907 – – 5,907
2019 12 31 7,539 – – 7,539
6,855 19,811 98 26,764
2020 12 31 14,394 19,811 98 34,303
2019 1 1 177 – – 177
1,071 – – 1,071
2019 12 31 1,248 – – 1,248
2,029 – 7 2,036
2020 12 31 3,277 – 7 3,284
2020 12 31 11,117 19,811 91 31,019
2019 12 31 6,291 – – 6,291
20% 50%
10%
2020 8 28
19,811,000
230
2020 12 31
17.
12 31
2020 2019
1,000 1,000
21 22
1,021 1,022
2020 2019 2020 2019
12 31 12 31 12 31 12 31
50% 50% 50% 50%
50% 50%
2020 12 31
231
2020 12 31
17.
12 31
2020 2019
2,042 2,044
12 31
2020 2019
(2) (10)
12 31
2020 2019
2,042 2,044
50% 50%
1,021 1,022
232
2020 12 31
18.
2019 3 19 2,900,000
36.71% 2020 12 2019 9 11
10,000,000 70,846,000 Anwita Biosciences, Inc. Anwita
20%
12 31
2020 2019
70,846 73,746
(5,696) (2,522)
65,150 71,224
2020 2019 2020 2019
12 31 12 31 12 31 12 31
36.71% 36.71%
Anwita 20% 20% 20% 20%
50% 50%
50% 50%
2020 12 31
233
2020 12 31
18.
Anwita
12 31
2020 2019
47,815 73,904
13,159 9,295
(7,466) (4,008)
(343) (3,182)
2019
2020 9 11
12 31 2019
12 31
14,176 –
(18,602) (9,876)
234
2020 12 31
18.
Anwita
12 31
2020 2019
Anwita 53,165 76,009
Anwita 20% 20%
Anwita 10,633 15,202
55,010 55,010
(493) (1,341)
Anwita 65,150 68,871
Anwita
2020 12 2,900,000
2,900
20% (2,270)
630
19.
12 31
2020 2019
277,288 129,081
31,887 35,004
34,250 16,581
343,425 180,666
235
2020 12 31
20.
12 31
2020 2019
589,207 157,505
74,116 –
663,323 157,505
– (89)
663,323 157,416
2019 1 1
12 31
2020 2019
0 30 573,437 96,647
31 90 27,876 60,235
91 180 61,103 534
180 907 –
663,323 157,416
2020 12 31 61,583,000 2019
8,540,000 90
2020 12 31 74,116,000
2019
37
236
2020 12 31
21.
12 31
2020 2019
24,523 4,548
12,754 8,584
a 265,524 300,927
b 130,674 201,156
c
1,176 6,099
d
2,715 5,430
e
13,948 25,371
154,297 125,726
f
– 10,376
605,611 688,217
(932) (588)
604,679 687,629
306,954 352,163
297,725 335,466
604,679 687,629
237
2020 12 31
21.
(a)
(b)
(c)
(d) 2016 12 13,574,000
60%
8,144,000 15,000 8,159,000 2017 8
20% 2,715,000 2020 12 20%
2,715,000 2019 5,430,000 2020
12 31
(e) 2020 12 31 13,948,000 2019
25,371,000
154,297,000 2019 125,726,000 2020
12 31
(f) 2019 12 31
37
238
2020 12 31
22.
12 31
2020 2019
17 17
a 77,030 –
b 133,007 69,345
c 146,688 –
356,725 69,345
(a)
(b)
(c)
68,199,000
23.
2020 4 30
2020 12 31 0.01% 3.3% 2019 0.3% 3.6%
37
239
2020 12 31
24.
12 31
2020 2019
90,706 74,616
106,018 112,561
a 215,933 98,561
31,656 14,979
– b 210,552 –
c 30,149 –
48,330 30,004
64,354 –
205,026 113,311
19,620 10,409
– 13,565
d 68,199 –
40 32,625 –
91,848 46,633
1,215,016 514,639
15 60 2019 15 60
12 31
2020 2019
0 30 74,433 58,726
31 60 4,316 2,946
61 180 2,009 11,426
180 9,948 1,518
90,706 74,616
240
2020 12 31
24.
(a)
(b) 5
30
(c)
(d) 22
25.
12 31
2020 2019
774,568 746,085
20,000 75,702
794,568 821,787
252,346 76,891
542,222 –
– 744,896
794,568 821,787
(252,346) (76,891)
542,222 744,896
2020 2019 12 31
241
2020 12 31
25.
12 31
2020 2019
3.75% 5.23% 4.35% 5.23%
2020 2019
1,716,673 1,607,916
58,862 62,425
1,775,535 1,670,341
26.
2019 7 5
228,242,800
2019 12 31
2019 1 1 241,763
7 (13,520)
(28,243)
(200,000)
2019 12 31 –
242
2020 12 31
27.
12 31
2020 2019
a 71,506 35,795
b 32,303 20,525
103,809 56,320
103,809 56,320
(a)
(b)
28.
12 31
2020 2019
25,220 13,846
16,942 11,042
14,049 16,290
56,211 41,178
12 (25,220) (13,846)
12 30,991 27,332
5.22% 2019 5.22%
243
2020 12 31
29.
12 31
2020 2019
26,113 20,590
2019 1 1 4 – – 1,284 1,288
23 – 939 18,340 19,302
2019 12 31 27 – 939 19,624 20,590
(21) 468 (117) 5,193 5,523
2020 12 31 6 468 822 24,817 26,113
244
2020 12 31
29.
2020 12 31 392,746,000 2019 41,463,000
3,691,921,000 2019 2,073,125,000
2020 12 31 6,432,000 2019
3,864,000 161,956,000 2019 97,684,000
12 31
2020 2019
304,327 –
39,207 10,980
35,720 23,764
3,529,965 1,975,441
7,060 2,855
3,916,279 2,013,040
3,482,986,000 2019 1,965,938,000
46,979,000 2019
9,503,000 2020 2019 12 31
245
2020 12 31
30.
1.0
2019 1 1 760,310,000 760,310
H a 23,836,500 23,837
2019 12 31 784,146,500 784,147
A b 87,130,000 87,130
32 1,219,500 1,219
2020 12 31 872,496,000 872,496
(a) 2019 1 9 19.38
16.94 23,836,500 H 461,951,000 403,838,000
23,836,500
380,001,500
(b) 2020 7 15 55.50 87,130,000 A
4,835,715,000 87,130,000
4,748,585,000 A
246
2020 12 31
31.
12 31
2020 2019
387,582 427,095
15,000 –
125,000 –
140,000 –
32.
2018 3 12
6,023,000 9.2 2018 5
14
2018 3 12 12 25%
2018 3 12 24 35%
2018 3 12 36 40%
247
2020 12 31
32.
2019 12 31 2020 5
11
9 4
2020 12 31 3,666,700 2019 5,213,000
0.42% 2019 0.66%
2020 12 31
2020 2020
1 1 12 31
2018 5 14 9.20 2019 3 12 2019 3 12 2020 3 12 2020 12 15 1,303,250 – (1,219,500) (83,750) –
2018 5 14 9.20 2020 3 12 2020 12 16 2021 3 12 2021 12 15 1,824,550 – – (113,050) 1,711,500
2018 5 14 9.20 2021 3 12 2021 12 16 2022 3 12 2022 12 15 2,085,200 – – (130,000) 1,955,200
5,213,000 – (1,219,500) (326,800) 3,666,700
1,711,500
– 9.20 9.20 9.20
248
2020 12 31
32.
2019 12 31
2019 2019
1 1 12 31
2018 5 14 9.20 2019 3 12 2019 3 12 2019 3 12 2020 3 12 1,449,500 – (146,250) 1,303,250
2018 5 14 9.20 2020 3 12 2020 3 12 2020 3 12 2021 3 12 2,029,300 – (204,750) 1,824,550
2018 5 14 9.20 2021 3 12 2021 3 12 2021 3 12 2022 3 12 2,319,200 – (234,000) 2,085,200
5,798,000 – (585,000) 5,213,000
1,303,250
9.20 – 9.20 9.20
A 77.83
2020 12 31 6,158,000 2019
11,797,000 391,000 2019 3,841,000
249
2020 12 31
32.
A
2020 11 16
A A
A 28,519,000
2020 11 16 12 40%
2020 11 16 24 30%
2020 11 16 36 30%
A
2020 2020
1 1 12 31
2020 11 16 2021 11 16 2022 11 16 – 11,407,600 – 11,407,600
2020 11 16 2022 11 16 2023 11 16 – 8,555,700 – 8,555,700
2020 11 16 2023 11 16 2024 11 16 – 8,555,700 – 8,555,700
– 28,519,000 – 28,519,000
2020 12 31 24,570,000 995,000
250
2020 12 31
33.
50
4% 2%
2020 12 31
26,895,000 2019 38,748,000
1,257,000 2019 1,079,000
34.
(a)
12 31
2020 2019
– 840
United-Power Pharma Tech Co., Ltd UPPT – 11,115
Anwita 13,156 –
13,156 11,955
UPPT
2019 12 31 UPPT
251
2020 12 31
34.
(b)
12 31
2020 2019
QHHH – 456
QHHH
(c)
12 31
2020 2019
159 –
(d)
12 31
2020 2019
115,029 42,711
6,928 403
518 675
122,475 43,789
252
2020 12 31
35.
2020 2019 12 31
2020 2019
12 31 12 31
Shanghai Junshi Biotechnology Co., Ltd.* 1,000,000,000 100% 100%
2016 6 29 805,000,000
Jiangsu Union Biopharm 60,000,000 100% 100%
Pharmaceutical Technology Co., Ltd.* 2013 4 1 45,000,000
Suzhou Junmeng Biosciences Co., Ltd.* 600,000,000 100% 100%
2013 10 12 405,000,000
Taizhou Junshi Biosciences Co., Ltd.* 5,000,000 100% 100%
2014 5 9
Suzhou Union Biopharm Biosciences Co., Ltd.* 750,000,000 100% 100%
2013 10 12 672,500,000
253
2020 12 31
35.
2020 2019
12 31 12 31
Suzhou Junshi Biosciences Co., Ltd.* 500,000,000 100% 100%
2017 7 26 155,419,000
Shenzhen Qianhai Junshi Hospital 50,000,000 51% 51%
Investment Management Co., Ltd* 2015 12 11
TopAlliance Biosciences Inc. 50,000,000 100% 100%
2013 3 6 326,563,000
50,000,000
326,563,000
:
Beijing Union Biopharm Junshi 25,000,000 100% 100%
Biosciences Co., Ltd.* 2016 6 12 11,200,000
Suzhou Junao Medicine Co., Ltd.* 300,000,000 100% 100%
2018 1 10 48,252,000
254
2020 12 31
35.
2020 2019
12 31 12 31
Suzhou Junshi Biotechnology Co., Ltd.* 200,000,000 100% 100%
2018 6 19 73,665,452
Junshi Hong Kong Limited 10,000,000 100% 100%
2019 4 23 1
Suzhou Junyou Hospital Management Co., Ltd.* 50,000,000 100% –
2020 11 17
*
255
2020 12 31
36.
37.
37a.
12 31
2020 2019
4,088,557 1,402,343
356,742 69,362
1,279,634 910,718
37b.
256
2020 12 31
37.
37b.
(i)
12 31
2020 2019
608,851 610,381
11 14
(72,394) (7,367)
– (255)
(4,036) –
5% 2019 5% 5%
5% 5%
5% 5%
257
2020 12 31
37.
37b.
(i)
12 31
2020 2019
(20,117) (22,613)
(ii)
25 28
23 21
12 31
2020 2019
20,278 29,222
258
2020 12 31
37.
37b.
(ii)
12 31
2020 2019
26,312 11,011
(iii)
22
2 5% 2019
5% 2020 12 31 9,230,000 2019
2,567,000 3
37
259
2020 12 31
37.
37b.
12
12
2020 12 31
64% 2019 100% 53% 2019
32%
260
2020 12 31
37.
37b.
89,000 2019 89,000
12
2020 2019 12 31
344,000 2019 1,127,000
– 12
– 12
– –
261
2020 12 31
37.
37b.
– –
12
2020 2019
23 AA 12 – 6,828
23 AA 12 3,384,998 1,214,026
21 12 41,168 24,661
20
253,512 99,440
335,695 58,065
74,116 –
4,089,489 1,403,020
9
262
2020 12 31
37.
37b.
2020 2019
0.01% 0.1% 253,512 0.01% 0.1% 90,901
1-30 – 0.1% 5% 7,989
31-60 – 1.5% 10% 550
253,512 99,440
2020 12 31
89,000 2019 89,000 2019 12 31
89,000
263
2020 12 31
37.
37b.
12
2019 1 1 – 1,715 1,715
2019 1 1
– (1,127) (1,127)
89 – 89
2019 12 31 89 588 677
2020 1 1
(89) (326) (415)
– 670 670
2020 12 31 – 932 932
25 30
264
2020 12 31
37.
37b.
3
3 1 1-2 2-5
%
2020 12 31
– 485,066 – – – 485,066 485,066
5.23 11,336 281,416 582,629 – 875,381 794,568
5.22 8,503 23,007 17,770 21,887 71,167 56,211
504,905 304,423 600,399 21,887 1,431,614 1,335,845
2019 12 31
– 88,931 – – – 88,931 88,931
5.14 50,221 66,454 38,921 782,087 937,683 821,787
5.22 4,681 14,194 12,932 16,836 48,643 41,178
143,833 80,648 51,853 798,923 1,075,257 951,896
265
2020 12 31
37.
37b.
(i)
2020 2019
12 31 12 31
17 17
1,952 15,000
27% 2019 24% a
EV/S EV/S 8.69 2019 5.44 b
3,772 3,000
27% 2019 26% c
P/R&D P/R&D 2.80 2019 4.70 d
89,373 51,345 2020 2020 2020
2019 P/R&D 26% e
P/R&D 17.52 f
2019 2019
266
2020 12 31
37.
37b.
(i)
2020 2019
12 31 12 31
37,910 –
146,688 –
77,030 –
g
a.
0.5% 27.5%/26.5% 2019 24.5%/23.5%
2020 12 31 13,000 2019
100,000 13,000 2019 100,000
b. EV/S
EV/S 5% 9.12/8.26 2019 5.71/5.17
2020 12 31 55,000 2019
713,000 55,000 2019 713,000
267
2020 12 31
37.
37b.
(i)
c.
0.5% 27.5%/26.5% 2019
26.5%/25.5% 2020 12 31 26,000
2019 21,000 26,000 2019 21,000
d. P/R&D
P/R&D 5% 2.94/2.66 2019
4.93/4.46 2020 12 31 188,000
2019 157,000 188,000 2019 157,000
e.
0.5% 26.5%/25.5% 2020
12 31 604,000 604,000
f. P/R&D
P/R&D 5% 18.40/16.64
2020 12 31 4,469,000 4,469,000
g.
5% 2020 12 31
3,852,000
268
2020 12 31
37.
37b.
(ii)
2019 1 1 – – (241,763) (241,763)
18,000 – – 18,000
– – 13,520 13,520
– – 28,243 28,243
– – 200,000 200,000
2019 12 31 2020 1 1 18,000 – – 18,000
51,345 – – 51,345
– 60,000 – 60,000
(106) – – (106)
25,858 17,030 – 42,888
2020 12 31 95,097 77,030 – 172,127
2019 12 31
13,520,000 9,906,000
(iii)
269
2020 12 31
38.
28 25 26 24
2019 1 1 46,468 328,632 241,763 14,415 631,278
(17,556) 461,312 (228,243) (27,717) 187,796
2,289 31,423 – – 33,712
– – – 14,721 14,721
H – – – 12,146 12,146
– – (13,520) – (13,520)
9,977 – – – 9,977
– 420 – – 420
2019 12 31 41,178 821,787 – 13,565 876,530
(25,348) (70,334) – (337,730) (433,412)
3,079 43,115 – – 46,194
– – – 324,165 324,165
37,302 – – – 37,302
2020 12 31 56,211 794,568 – – 850,779
16,803,000 2019 20,412,000
270
2020 12 31
39.
12 31
2020 2019
220,642 37,645
34,660 36,558
1,875,400 1,791,838
27,962 4,427
1,021 1,022
65,150 68,871
42,494 134,003
343,480 69,345
2,610,809 2,143,709
271
2020 12 31
39.
12 31
2020 2019
41,041 26,514
596,481 113,416
237,128 226,369
782,571 158,230
2,641,560 944,648
4,298,781 1,469,177
954,387 304,994
– 75,702
161,579 396,457
18,077 10,478
1,134,043 787,631
3,164,738 681,546
5,775,547 2,825,255
30,961 21,218
18,600 25,987
49,561 47,205
5,725,986 2,778,050
872,496 784,147
4,853,490 1,993,903
5,725,986 2,778,050
272
2020 12 31
39.
2019 1 1 3,762,720 – 21,700 (9,367) (999,463) 2,775,590
– – – – (1,165,180) (1,165,180)
H 380,001 – – – – 380,001
H (12,146) – – – – (12,146)
– – 15,638 – – 15,638
– – – 9,367 (9,367) –
2019 12 31 4,130,575 – 37,338 – (2,174,010) 1,993,903
– – – – (1,592,375) (1,592,375)
A 4,748,585 – – – – 4,748,585
A (338,737) – – – – (338,737)
– – 6,549 – – 6,549
21,110 – (11,110) – – 10,000
– 25,565 – – – 25,565
2020 12 31 8,561,533 25,565 32,777 – (3,766,385) 4,853,490
9
H
273
2020 12 31
40.
2021 2 1 Coherus Biosciences, Inc. Coherus
Coherus (i)
530,000,000 2020
12 31 Coherus 5,000,000 32,625,000
24 (ii) 16
290,000,000
274
2018
2018 2019 7
2018 2018 5 14
2020 7 15
2020 A 2020 11 16 2020 2020
A 2020 H
2020 A
ASCO
A 1.00
A A
2021 6 29
50%
BLA
275
CGMP
622
1.00
2020
5 8
2020 7 15 A
FDA
GMP
2018
H H 2018 12 24
H 1.00
H H
276
IND
NDA
NMPA
2018
2018 12 11
277
2020 12 31
2020 A
A 2020 A
571
2016 6
2018 3
1.00 H A
A 2020 7 15
278
TopAlliance TopAlliance Biosciences Inc.
%
*